The efficacy of cyclophosphamide (CY), vincristine (VCR) and prednisolone (PRE) were studied in leukemia-bearing zebrafish larvae. A transplantable T-cell acute lymphoblastic leukemia (T-ALL) line ZL1 was induced by mosaic expression of zRag2-EGFP-mMyc transgene and underwent more than 20 consecutive transplantations in adult syngeneic fish prior to the experiments. Drug efficiency was assessed by an increase of lifespan (ILS) of treated leukemia-bearing animals as compared with untreated leukemia-bearing animals. Different doses of the drugs and length of the treatment were tested. CY and VCR demonstrated therapeutic effect which was dose- and time course-dependent. The maximal increase of ILS reached 61.1% after CY (400 mg/L, 72 h) treatment and 44.4%-in VCR (4 mg/L, 72 h) treated animals. None of the tumor-bearing larvae showed complete recovery from leukemia as a result of any VCR and CY monotherapy schedule. PRE was inefficient for treatment of leukemia in zebrafish in a dose range between 1 and 50 mg/L and a treatment length between 24 and 72 h due to it toxicity exclusively towards leukemia-bearing larvae. These data demonstrate that, in addition to morphological and genetic similarities with mammalian leukemia, zebrafish T-ALL is also sensitive to the same chemotherapeutic drugs in vivo as mammals. Therefore, this model can be utilized as a cost effective system for experimental tumor therapy and large-scale screening of anticancer compounds.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4161/cbt.9.11.11667 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Benchmarking miRNA reference genes in B-cell precursor acute lymphoblastic leukemia.
Sci Rep
November 2024
Department of Pediatrics and Adolescent Medicine, Ulm University Medical Center, Ulm, Germany.
MicroRNAs (miRNAs) play dual roles in acute lymphoblastic leukemia (ALL) as both tumor suppressors and oncogenes, and miRNA expression profiles can be used for patient risk stratification. Precise assessment of miRNA levels is crucial for understanding their role and function in gene regulation. Quantitative real-time polymerase chain reaction (qPCR) is a reliable, rapid, and cost-effective method for analyzing miRNA expression, assuming that appropriate normalization to stable references is performed to ensure valid data.
View Article and Find Full Text PDFGeneration of antitumor chimeric antigen receptors incorporating T cell signaling motifs.
Sci Signal
July 2024
Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 USA.
Chimeric antigen receptor (CAR) T cells have been used to successfully treat various blood cancers, but adverse effects have limited their potential. Here, we developed chimeric adaptor proteins (CAPs) and CAR tyrosine kinases (CAR-TKs) in which the intracellular ζ T cell receptor (TCRζ) chain was replaced with intracellular protein domains to stimulate signaling downstream of the TCRζ chain. CAPs contain adaptor domains and the kinase domain of ZAP70, whereas CAR-TKs contain only ZAP70 domains.
View Article and Find Full Text PDFTargeted Metabolomics of Tissue and Plasma Identifies Biomarkers in Mice with NOTCH1-Dependent T-Cell Acute Lymphoblastic Leukemia.
Int J Mol Sci
June 2024
Dipartimento di Scienze Chirurgiche, Oncologiche e Gastroenterologiche, Università di Padova, 35128 Padova, Italy.
While the genomics era has allowed remarkable advances in understanding the mechanisms driving the biology and pathogenesis of numerous blood cancers, including acute lymphoblastic leukemia (ALL), metabolic studies are still lagging, especially regarding how the metabolism differs between healthy and diseased individuals. T-cell ALL (T-ALL) is an aggressive hematological neoplasm deriving from the malignant transformation of T-cell progenitors characterized by frequent NOTCH1 pathway activation. The aim of our study was to characterize tumor and plasma metabolomes during T-ALL development using a NOTCH1-induced murine T-ALL model (ΔE-NOTCH1).
View Article and Find Full Text PDFOptimization of In Vitro Th17 Polarization for Adoptive Cell Therapy in Chronic Lymphocytic Leukemia.
Int J Mol Sci
June 2024
Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA.
Article Synopsis
- Preclinical studies have shown that in vitro-differentiated Th17 cells can be effective in solid tumors, but their potential in enhancing adoptive cell therapy (ACT) for hematological cancers like chronic lymphocytic leukemia (CLL) is not yet explored.
- CLL, a type of B-cell cancer, faces issues with resistance to targeted therapies, and existing T-cell treatments like CAR T cells have seen limited success due to T-cell dysfunction and immunosuppressive responses.
- This research highlights the successful polarization of CD4 T cells into a Th17 phenotype from a CLL mouse model, demonstrating improved memory properties and persistence in treating leukemia, marking a significant step towards enhancing ACT efficacy in CLL with Th17 CAR T
Exercise-induced β2-adrenergic Receptor Activation Enhances the Antileukemic Activity of Expanded γδ T-Cells via DNAM-1 Upregulation and PVR/Nectin-2 Recognition.
Cancer Res Commun
May 2024
School of Nutritional Sciences and Wellness, University of Arizona, Tucson, Arizona.
Unlabelled: Exercise mobilizes cytotoxic lymphocytes to blood which may allow superior cell products to be harvested and manufactured for cancer therapy. Gamma-Delta (γδ) T-cells have shown promise for treating solid tumors, but there is a need to increase their potency against hematologic malignancies. Here, we show that human γδ T-cells mobilized to blood in response to just 20 minutes of graded exercise have surface phenotypes and transcriptomic profiles associated with cytotoxicity, adhesion, migration, and cytokine signaling.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!